American Century Companies Inc. Purchases 418,603 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

American Century Companies Inc. lifted its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 30.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,809,897 shares of the medical instruments supplier’s stock after acquiring an additional 418,603 shares during the period. American Century Companies Inc. owned approximately 2.45% of OraSure Technologies worth $7,710,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Factorial Partners LLC increased its holdings in shares of OraSure Technologies by 86.3% in the 2nd quarter. Factorial Partners LLC now owns 303,627 shares of the medical instruments supplier’s stock worth $1,293,000 after purchasing an additional 140,627 shares in the last quarter. Koss Olinger Consulting LLC bought a new stake in OraSure Technologies in the 2nd quarter worth about $327,000. Acadian Asset Management LLC raised its position in OraSure Technologies by 38.1% in the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock worth $9,349,000 after buying an additional 605,324 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in OraSure Technologies by 74.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 163,542 shares of the medical instruments supplier’s stock valued at $697,000 after acquiring an additional 69,625 shares during the period. Finally, Shikiar Asset Management Inc. purchased a new stake in shares of OraSure Technologies during the 2nd quarter valued at about $96,000. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OSUR has been the topic of several research reports. Evercore ISI raised their target price on shares of OraSure Technologies from $4.50 to $5.00 and gave the stock an “in-line” rating in a report on Wednesday, August 7th. StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Saturday, August 17th. Three research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $6.67.

OraSure Technologies Trading Up 1.8 %

OSUR opened at $4.41 on Tuesday. The firm’s 50 day simple moving average is $4.33 and its two-hundred day simple moving average is $4.91. The company has a market capitalization of $326.16 million, a PE ratio of 14.70 and a beta of 0.05. OraSure Technologies, Inc. has a 1-year low of $3.91 and a 1-year high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share for the quarter. The company had revenue of $54.34 million for the quarter, compared to the consensus estimate of $53.35 million. OraSure Technologies had a return on equity of 9.15% and a net margin of 9.88%. Equities analysts forecast that OraSure Technologies, Inc. will post -0.11 earnings per share for the current fiscal year.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.